Here is the critical distinction
Last Published 04.01.2026 Effective Date: 04.01.2026 This policy addresses the use of Enjaymo (sutimlimab-jome) for the treatment of cold agglutinin disease (CAD)
Yes, and this is something we take seriously
So, 10 months ago, James started taking Wegovy
Further studies with larger populations and longer follow-up periods are needed to assess the impact of these medications on the incidence of cardiovascular events, the leading cause of mortality and morbidity in this population
Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial